NOTCH1, TP53, and MAP2K1 mutations in splenic diffuse red pulp small B-cell lymphoma are associated with progressive disease

American Journal of Surgical Pathology

Volumn 40, Issue 2, 2016, Pages 192-201

  Martinez, Daniel ^a,b   Navarro, Alba ^c   Martinez Trillos, Alejandra ^a   Molina Urra, Ricardo ^d   Gonzalez Farre, Blanca ^a   Salaverria, Itziar ^c   Nadeu, Ferran ^c   Enjuanes, Anna ^c   Clot, Guillem ^c   Costa, Dolors ^a   Carrio, Ana ^a   Villamor, Neus ^a,c   Colomer, Dolors ^a,c   Martinez, Antonio ^a,b   Bens, Susanne ^e   Siebert, Reiner ^e   Wotherspoon, Andrew ^f   Bea, Silvia ^c   Matutes, Estella ^a   Campo, Elias ^a,b,c  

^a Institut Clinic de Malalties Digestives i Metaboliques   (United States)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d Hospital Regional de Puerto Montt   (Chile)

^e UNIVERSITY OF KIEL   (Germany)

^f ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

BRAF; MAP2K1; NOTCH1; Prognosis; SF3B1; TP53

Indexed keywords

MAP2K1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; NOTCH1 PROTEIN, HUMAN; NOTCH1 RECEPTOR; PROTEIN P53; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; BIOPSY; CHEMISTRY; CHILE; CLINICAL TRIAL; COPY NUMBER VARIATION; DISEASE COURSE; DISEASE FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; EUROPE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE DOSAGE; GENE REARRANGEMENT; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; MOLECULAR DIAGNOSIS; MULTICENTER STUDY; MUTATION; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; RISK FACTOR; SPLENIC NEOPLASMS; TIME FACTOR;

ADULT; AGED; BIOMARKERS, TUMOR; BIOPSY; CHILE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; EUROPE; FEMALE; GENE DELETION; GENE DOSAGE; GENE REARRANGEMENT; GENES, IMMUNOGLOBULIN HEAVY CHAIN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LYMPHOMA, B-CELL; MALE; MAP KINASE KINASE 1; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RECEPTOR, NOTCH1; RISK FACTORS; SPLENIC NEOPLASMS; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84958036005     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000523     Document Type: Article

References (39)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
2. Kanellis G, Mollejo M, Montes-Moreno S, et al. Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features. Haematologica. 2010;95:1122-1129.
3. Mollejo M, Algara P, Mateo MS, et al. Splenic small B-cell lymphoma with predominant red pulp involvement: a diffuse variant of splenic marginal zone lymphoma? Histopathology. 2002;40:22-30.
4. Traverse-Glehen A, Baseggio L, Bauchu EC, et al. Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity? Blood. 2008;111:2253-2260.
5. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364:2305-2315.
6. Kiel MJ, Velusamy T, Betz BL, et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med. 2012;209:1553-1565.
7. Martinez N, Almaraz C, Vaque JP, et al. Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation. Leukemia. 2014;28: 1334-1340.
8. Rossi D, Trifonov V, Fangazio M, et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med. 2012; 209:1537-1551.
9. Waterfall JJ, Arons E, Walker RL, et al. High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet. 2014;46:8-10.
10. Shao H, Calvo KR, Gronborg M, et al. Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria. Leuk Res. 2013;37:401-409.
11. Xi L, Arons E, Navarro W, et al. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood. 2012;119:3330-3332.
12. Raess PW, Mintzer D, Husson M, et al. BRAF V600E is also seen in unclassifiable splenic B-cell lymphoma/leukemia, a potential mimic of hairy cell leukemia. Blood. 2013;122:3084-3085.
13. Ventura RA, Martin-Subero JI, Jones M, et al. FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn. 2006;8: 141-151.
14. Salaverria I, Royo C, Carvajal-Cuenca A, et al. CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. Blood. 2013;121:1394-1402.
15. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586.
16. Petit B, Parrens M, Soubeyran I, et al. Among 157 marginal zone lymphomas, DBA.44(CD76) expression is restricted to tumour cells infiltrating the red pulp of the spleen with a diffuse architectural pattern. Histopathology. 2009;54:626-631.
17. Saadoun D, Suarez F, Lefrere F, et al. Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? Blood. 2005;105:74-76.
18. Shimizu-Kohno K, Kimura Y, Kiyasu J, et al. Malignant lymphoma of the spleen in Japan: a clinicopathological analysis of 115 cases. Pathol Int. 2012;62:577-582.
19. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475:101-105.
20. Salido M, Baro C, Oscier D, et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood. 2010;116:1479-1488.
21. Hockley SL, Morgan GJ, Leone PE, et al. High-resolution genomic profiling in hairy cell leukemia-variant compared with typical hairy cell leukemia. Leukemia. 2011;25:1189-1192.
22. Amakawa R, Ohno H, Fukuhara S. t(9;14)(p13;q32) involving the PAX-5 gene: a unique subtype of 14q32 translocation in B cell non-Hodgkin's lymphoma. Int J Hematol. 1999;69:65-69.
23. Poppe B, De PP, Michaux L, et al. PAX5/IGH rearrangement is a recurrent finding in a subset of aggressive B-NHL with complex chromosomal rearrangements. Genes Chromosomes Cancer. 2005;44: 218-223.
24. Virgilio L, Narducci MG, Isobe M, et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci USA. 1994;91:12530-12534.
25. Aggarwal M, Villuendas R, Gomez G, et al. TCL1A expression delineates biological and clinical variability in B-cell lymphoma. Mod Pathol. 2009;22:206-215.
26. Arons E, Kreitman RJ. Molecular variant of hairy cell leukemia with poor prognosis. Leuk Lymphoma. 2011;52(suppl 2):99-102.
27. Bikos V, Darzentas N, Hadzidimitriou A, et al. Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications. Leukemia. 2012;26:1638-1646.
28. Hockley SL, Giannouli S, Morilla A, et al. Insight into the molecular pathogenesis of hairy cell leukaemia, hairy cell leukaemia variant and splenic marginal zone lymphoma, provided by the analysis of their IGH rearrangements and somatic hypermutation patterns. Br J Haematol. 2010;148:666-669.
29. Navarro A, Clot G, Royo C, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012;72:5307-5316.
30. Bea S, Valdes-Mas R, Navarro A, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci USA. 2013;110:18250-18255.
31. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med. 2011;208:1389-1401.
32. Kridel R, Meissner B, Rogic S, et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood. 2012;119:1963-1971.
33. Villamor N, Conde L, Martinez-Trillos A, et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia. 2013;27:1100-1106.
34. Karube K, Martinez D, Royo C, et al. Recurrent mutations of NOTCH genes in follicular lymphoma identify a distinctive subset of tumours. J Pathol. 2014;234:423-430.
35. Ouillette P, Saiya-Cork K, Seymour E, et al. Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia. Clin Cancer Res. 2013;19:2893-2904.
36. Mansour MR, Duke V, Foroni L, et al. Notch-1 mutations are secondary events in some patients with T-cell acute lymphoblastic leukemia. Clin Cancer Res. 2007;13:6964-6969.
37. Chakraborty R, Hampton OA, Shen X, et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood. 2014;124:3007-3015.
38. Brown NA, Furtado LV, Betz BL, et al. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood. 2014;124:1655-1658.
39. Hockley SL, Else M, Morilla A, et al. The prognostic impact of clinical and molecular features in hairy cell leukaemia variant and splenic marginal zone lymphoma. Br J Haematol. 2012; 158:347-354.